Overview

ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS

Status:
Active, not recruiting
Trial end date:
2026-03-31
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate the safety of reducing dual antiplatelet therapy (DAPT) duration to 1 month after implantation of the everolimus-eluting cobalt-chromium stent (CoCr-EES) under the setting of acute coronary syndrome (ACS).
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Kyoto University, Graduate School of Medicine
Treatments:
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Criteria
Inclusion Criteria:

- Patients received percutaneous coronary intervention with cobalt-chromium
everolimus-eluting stent under the setting of acute coronary syndrome

- Patients who are capable of oral dual antiplatelet therapy consisting of aspirin and
P2Y12 receptor antagonist

Exclusion Criteria:

- Patients requiring oral anticoagulants

- Patients with medical history of intracranial hemorrhage

- Patients who have experienced serious complications (myocardial infarction, stroke,
and major bleeding) during hospital stay after percutaneous coronary intervention

- Patients with drug eluting stents other than Cobalt chromium everolimus eluting stents
implanted at the time of enrollment

- Patients confirmed to have no tolerability to clopidogrel before enrollment

- Patients requiring continuous administration of antiplatelet drugs other than aspirin
and P2Y12 receptor antagonists at the time of enrollment